Biosensia is a science focused, venture backed business established specifically to develop and exploit this novel and proprietary technology, RapiPlex.

RapiPlex is a point-of- care diagnosis system based on a set of proprietary technologies capable of producing quantitative and qualitative laboratory quality test results across multiple analytes.

ACT Venture Capital is an early stage investor in Biosensia with syndicate partners Seroba LifeScience Partners, Atlantic Bridge and Street Capital.